Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Imugene Limited ( (AU:IMU) ) has shared an update.
Imugene Limited announced several key developments in its recent quarterly activities report. The company achieved a significant milestone in its MAST trial, with a bile tract cancer patient maintaining a complete response for over two years, indicating the potential durability of their oncolytic virotherapy. Furthermore, they have opened a bile tract cancer expansion cohort for more patient enrollment. The company also dosed the first patient in the onCARlytics trial and initiated patient recruitment in Australia for the azer-cel trial targeting diffuse large B-cell lymphoma. Financially, Imugene raised $20 million through convertible notes and warrants, with potential for an additional $26 million, and received an $11.7 million R&D tax refund for FY23, bolstering their financial position.
More about Imugene Limited
Imugene Limited is a clinical-stage immuno-oncology company that focuses on developing novel therapies for the treatment of cancer. The company is involved in creating treatments that harness the immune system to target and eradicate tumors, primarily through innovative virotherapy and cell therapy platforms.
YTD Price Performance: 20.0%
Average Trading Volume: 165,723
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $181.4M
For an in-depth examination of IMU stock, go to TipRanks’ Stock Analysis page.
